SCHEMBL23945753

SCHEMBL23945753

CC#CCOCCOCCCC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.44
CYP3A4 P08684 4/20 0.43
HTT P42858 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
THRB P10828 1/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 4/20 0.33
HPGD P15428 1/20 0.33
ADRB2 P07550 1/20 0.33
ADRB1 P08588 1/20 0.33
ADRB3 P13945 1/20 0.33
RAB9A P51151 2/20 0.31
LMNA P02545 2/20 0.31
NPC1 O15118 1/20 0.31
ATM Q13315 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
ALDH1A1 P00352 2/20 0.31
RARB P10826 1/20 0.31
USP2 O75604 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8734941 0.95
SCHEMBL26280819 0.86 HSD17B10 (0.31)
SCHEMBL13007103 0.85 CYP3A4 (0.32) CYP3A4
SCHEMBL20658174 0.83 TSHR (0.48) TSHRCYP3A4HTTMEN1KMT2A
SCHEMBL3034850 0.80
SCHEMBL27902889 0.77 TSHR (0.67) TSHRCYP3A4HTTMEN1KMT2A
SCHEMBL1133315 0.77 TSHR (0.67) TSHRCYP3A4HTTMEN1KMT2A
SCHEMBL30673 0.77 TSHR (0.67) TSHRCYP3A4HTTMEN1KMT2A
SCHEMBL27130 0.77 TSHR (0.67) TSHRCYP3A4HTTMEN1KMT2A
SCHEMBL1132722 0.77 TSHR (0.67) TSHRCYP3A4HTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 TSHR 3319/4885CYP3A4 2542/4885HTT 2464/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 TSHR 3319/4885CYP3A4 2542/4885HTT 2464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.